On August 21, 2014, the Federal Circuit issued a decision in AbbVie Inc. v. The Mathilda and Terence Kennedy Institute of Rheumatology Trust., holding that the claims to a selection invention were invalid based on obviousness-type double patenting over claims in an earlier-expiring patent that dominated the selection invention.
Download the attached PDF for our analysis of the decision and its impact on claims to a selection invention.
Download
PDF
Stay in the Know
Receive insights from the most respected practitioners of IP law, straight to your inbox.
Subscribe for Updates